大疱性类天疱疮与新型联合检查点抑制剂免疫疗法相关
Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy.
作者信息
Fontecilla Natalia M., Khanna Trisha, Bayan Claire-Audrey Y., Antonov Nina A., Geskin Larisa J.
出版信息
J Drugs Dermatol. 2019 Jan 1;18(1):103-104.
Novel immunotherapies including antibodies to programmed death ligand 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have become common therapies for neoplasms including metastatic melanoma and non-small cell lung cancer (NSCLC). Dermatologic toxicity is the most common adverse event associated with these immunotherapies. We report a case of bullous pemphogoid (BP) in a patient receiving combination durvalumab and tremelimumab, two newer immunotherapy checkpoint inhibitors under investigation in phase III trials. J Drugs Dermatol. 2019;18(1):103-104.
包括程序性死亡配体1（PD-1）抗体和细胞毒性T淋巴细胞相关抗原4（CTLA-4）抗体在内的新型免疫疗法已成为转移性黑色素瘤和非小细胞肺癌（NSCLC）等肿瘤的常用治疗方法。皮肤毒性是与这些免疫疗法相关的最常见不良事件。我们报告了1例在接受度伐利尤单抗和曲美木单抗联合治疗的患者中发生大疱性类天疱疮（BP）的病例，这两种新型免疫疗法检查点抑制剂正处于Ⅲ期试验研究中。《药物皮肤病学杂志》。2019年；18(1):103 - 104。
Zotero 插件